DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow DXCM
DexCom, Inc. (DXCM) Shares outstanding
DexCom, Inc.'s shares outstanding at the end of fiscal 2025 was $405.5M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $390.1M. Over the past ten years it has ranged from $319.2M (fiscal 2015) to $428.8M (fiscal 2021); the current reading is higher than 55% of that period. DexCom, Inc. ranks 10th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $405.5M | (1.74%) |
| FY2024 | $412.7M | (3.01%) |
| FY2023 | $425.5M | (0.47%) |
| FY2022 | $427.5M | (0.30%) |
| FY2021 | $428.8M | 2.00% |
| FY2020 | $420.4M | 13.87% |
| FY2019 | $369.2M | 4.65% |
| FY2018 | $352.8M | 2.20% |
| FY2017 | $345.2M | 3.23% |
| FY2016 | $334.4M | 4.76% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $390.1M | (0.89%) |
| Mar 2026 | $393.6M | (2.93%) |
| Dec 2025 | $405.5M | (0.47%) |
| Sep 2025 | $407.4M | (0.20%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| BSX Boston Scientific Corporation compare | $1.5B |
| PHG Koninklijke Philips N.V. compare | $968.6M |
| EW Edwards Lifesciences Corporation compare | $577.6M |
| GEHC GE HealthCare Technologies Inc. compare | $454.0M |
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| DXCM DexCom, Inc. | $390.1M |
| ZBH Zimmer Biomet Holdings, Inc. compare | $192.8M |
| STE STERIS plc compare | $97.9M |
| PEN Penumbra, Inc. compare | $39.6M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement